The ENT-loaded LyP-1-modified nanosystem provided enhanced anti-tumor activity against KYSE-30 cells with direct targeting of tumor lymphatics, triggered nucleus rupture, mitochondrial degradation, decreased cell proliferation and migration, as well as restricted VEGF-C and MMP2 expression. The gene discussed is PTPN22; the disease is neoplasm.